{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-102387","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.113853+00:00","generated_at":"2026-05-17T20:55:21.425213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tango Therapeutics Q2 net loss $38.9M ($0.35/sh); Gilead collab truncated","bullets":["Net loss $38.9M ($0.35 per share) vs $25.6M ($0.24) in Q2 2024; revenue fell to $3.2M.","Cash $180.8M; expects to fund operations into Q1 2027.","Gilead collaboration research term trimmed from 7 to 5 yrs; $53.8M deferred revenue to be recognized in Q3 2025.","First patients dosed in TNG462 combo with Revolution Medicines RAS(ON) inhibitors and TNG456 Phase 1/2.","TNG462 monotherapy data expected 2H 2025; TNG260 clinical data also expected 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-102387","json":"https://secwatch.observer/filing/0000950170-25-102387.json","markdown":"https://secwatch.observer/filing/0000950170-25-102387.md","text":"https://secwatch.observer/filing/0000950170-25-102387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025102387/0000950170-25-102387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025102387/tngx-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:55:21.425213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}